Navigation Links
The California Healthcare Institute Responds to New Efforts to Repeal the Federal Medical Device Excise Tax
Date:2/7/2013

La Jolla, Calif. (PRWEB) February 07, 2013

The California Healthcare Institute (CHI) today released a statement in response to reintroduced legislation to repeal the 2.3 percent federal excise tax on medical device manufacturers.

“CHI strongly supports efforts to repeal the medical device excise tax, which threatens important research and development, and is already pressuring jobs at a time when we should be doing everything we can to encourage investment, innovation and job creation,” said CHI President and CEO David L. Gollaher, Ph.D. “As a tax on revenues, not profits, it especially discriminates against smaller device companies with pioneering ideas that have yet to reach the marketplace.”

Given the size and scope of the medical technology sector’s presence in California, the 2.3 percent tax has a disproportionate impact on the state. California is home to more than 1,200 medical technology companies — more than any other state in the nation — and the nearly 72,000 medical device jobs in California represent roughly 17 percent of the total U.S. medical technology workforce. Vibrant medical technology clusters exist in and around San Diego, San Francisco/Silicon Valley, Orange County and Sacramento, as well as the Los Angeles, Ventura/Santa Barbara, and Riverside/San Bernardino regions.

In California and nationwide, the tax has already had a negative effect on industry innovators, with large and small companies looking for ways to cut costs, which generally means hiring fewer workers and reducing investments in R&D.

CHI continues to work with California’s congressional representatives, including many who have signed on to co-sponsor the measure, in order to repeal this destructive tax. CHI applauds the bill’s original co-sponsors: John Campbell (R-Irvine), Susan Davis (D-San Diego), Jeff Denham (R-Turlock), Darrell Issa (R-Vista), Doug LaMalfa (R-Richvale), Scott Peters (D-San Diego), Ed Royce (R-Fullerton), David Valadao (R-Hanford) and Juan Vargas (D-San Diego).

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is http://www.chi.org. Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10409904.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
2. Precision Coating to Showcase Next Generation Coating Deposition Technology at MD&M West Show in Anaheim, California
3. California Biomedical Companies Report Higher Product Approvals, Fewer Delays
4. Bayer CropScience Announces Registration for use of Alion on Grapes in California
5. New "GMO Inside" Campaign Denounces Corporate Disinformation Campaign That Defeated Californias Prop 37
6. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
7. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
8. California Physical Therapists Prediction Proved "Right" by Results of State Board Audit
9. California Healthcare Institute Issues Statement on Supreme Court Ruling on the Affordable Care Act
10. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
11. Lightning Brewery’s Craft Beer Old Tempestuous Ale Wins Best of Show at 2012 California State Fair Commercial Brewing Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):